These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 38427337)

  • 21. Impact of rilpivirine cross-resistance on long-acting cabotegravir-rilpivirine in low and middle-income countries.
    Steegen K; Chandiwana N; Sokhela S; Venter WDF; Hans L
    AIDS; 2023 May; 37(6):1009-1011. PubMed ID: 36779485
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-Acting Cabotegravir for HIV Prevention: Issues of Access, Cost, and Equity.
    Sharfstein JM; Killelea A; Dangerfield D
    JAMA; 2022 Mar; 327(10):921-922. PubMed ID: 35157006
    [No Abstract]   [Full Text] [Related]  

  • 23. Long-acting injectable cabotegravir: implementation science needed to advance this additional HIV prevention choice.
    Schmidt HA; Rodolph M; Schaefer R; Baggaley R; Doherty M
    J Int AIDS Soc; 2022 Jul; 25(7):e25963. PubMed ID: 35903882
    [No Abstract]   [Full Text] [Related]  

  • 24. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial.
    Margolis DA; Gonzalez-Garcia J; Stellbrink HJ; Eron JJ; Yazdanpanah Y; Podzamczer D; Lutz T; Angel JB; Richmond GJ; Clotet B; Gutierrez F; Sloan L; Clair MS; Murray M; Ford SL; Mrus J; Patel P; Crauwels H; Griffith SK; Sutton KC; Dorey D; Smith KY; Williams PE; Spreen WR
    Lancet; 2017 Sep; 390(10101):1499-1510. PubMed ID: 28750935
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cabotegravir/Rilpivirine: the last FDA-approved drug to treat HIV.
    Taki E; Soleimani F; Asadi A; Ghahramanpour H; Namvar A; Heidary M
    Expert Rev Anti Infect Ther; 2022 Aug; 20(8):1135-1147. PubMed ID: 35596583
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quantum Mechanical-Based Stability Evaluation of Crystal Structures for HIV-Targeted Drug Cabotegravir.
    Han Y; Luo H; Lu Q; Liu Z; Liu J; Zhang J; Wei Z; Li J
    Molecules; 2021 Nov; 26(23):. PubMed ID: 34885762
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Brief Report: Impact of COVID-19 on Cabotegravir Plus Rilpivirine Long-Acting Dosing Across 6 Ongoing Global Phase IIb and III Clinical Trials.
    Czarnogorski M; Benn P; McCoig C; Nwafor T; Griffith S; Sutton K; Harrington C; Saggu P; Yague I; Williams W; Español CM; Goodchild J; Fricker J; Patel P; D'Amico R
    J Acquir Immune Defic Syndr; 2022 Oct; 91(2):157-161. PubMed ID: 36094481
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Compassionate use of long-acting cabotegravir plus rilpivirine for people living with HIV-1 in need of parenteral antiretroviral therapy.
    D'Amico R; Cenoz Gomis S; Moodley R; Van Solingen-Ristea R; Baugh B; Van Landuyt E; Van Eygen V; Min S; Cutrell A; Foster C; Chilton D; Allard SD; Ruiter A
    HIV Med; 2023 Feb; 24(2):202-211. PubMed ID: 35945163
    [TBL] [Abstract][Full Text] [Related]  

  • 29. People with HIV pioneers of injectable cabotegravir and rilpivirine long acting in Italy: who are they?
    Bartalucci C; Baldi F; Ricci E; Orofino G; Menzaghi B; Ferrara S; Pellicano' GF; Squillace N; Sarchi E; Pontali E; Cenderello G; Bargiacchi O; Piccica M; Carleo MA; Cascio A; De Socio GV; Bonfanti P; Di Biagio A
    AIDS; 2024 Mar; 38(3):430-434. PubMed ID: 38300162
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The propensity for long-acting cabotegravir and rilpivirine every 2 months among HIV-infected people eligible for treatment.
    Alberton F; Nozza S; Raccagni AR; Galli L; Spagnuolo V; Bossolasco S; Cernuschi M; Canetti D; Hasson H; Castagna A; Gianotti N
    J Med Virol; 2023 Jan; 95(1):e28330. PubMed ID: 36415058
    [No Abstract]   [Full Text] [Related]  

  • 31. Characterization of dolutegravir drug resistance in persons diagnosed with HIV after exposure to long-acting injectable cabotegravir for preexposure prophylaxis.
    Ahluwalia AK; Inzaule S; Baggaley RC; Vitoria M; Schaefer R; Schmidt HA; Rodolph M; Giron A; Jordan MR
    AIDS; 2022 Nov; 36(13):1897-1898. PubMed ID: 36172874
    [No Abstract]   [Full Text] [Related]  

  • 32. Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial.
    Margolis DA; Brinson CC; Smith GHR; de Vente J; Hagins DP; Eron JJ; Griffith SK; Clair MHS; Stevens MC; Williams PE; Ford SL; Stancil BS; Bomar MM; Hudson KJ; Smith KY; Spreen WR;
    Lancet Infect Dis; 2015 Oct; 15(10):1145-1155. PubMed ID: 26201299
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Implementation of a Pharmacist-Led, Long-Acting, Injectable Cabotegravir/Rilpivirine Program for HIV-1 at Health System-Based Clinics in the New York Metropolitan Area.
    Nguyen NM; Kavanagh R; Gozar M; Cabral D; Goetz H; Cha A; McGowan JP; Pao ML
    AIDS Patient Care STDS; 2024 Mar; 38(3):115-122. PubMed ID: 38471090
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development and validation of a multiplex UHPLC-MS/MS assay with stable isotopic internal standards for the monitoring of the plasma concentrations of the antiretroviral drugs bictegravir, cabotegravir, doravirine, and rilpivirine in people living with HIV.
    Courlet P; Alves Saldanha S; Cavassini M; Marzolini C; Choong E; Csajka C; Günthard HF; André P; Buclin T; Desfontaine V; Decosterd LA
    J Mass Spectrom; 2020 Jun; 55(6):e4506. PubMed ID: 32160389
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A cautionary note on entry and exit strategies with long-acting cabotegravir and rilpivirine.
    Ripamonti D; Rusconi S; Zazzi M
    AIDS; 2024 Feb; 38(2):263-265. PubMed ID: 38116723
    [No Abstract]   [Full Text] [Related]  

  • 36. Archived rilpivirine-associated resistance mutations among ART-naive and virologically suppressed people living with HIV-1 subtype C in Botswana: implications for cabotegravir/rilpivirine use.
    Maruapula D; Moraka NO; Bareng OT; Mokgethi PT; Choga WT; Seatla KK; Kelentse N; Koofhethille CK; Zuze BJL; Gaolathe T; Pretorius-Holme M; Makhema J; Novitsky V; Shapiro R; Moyo S; Lockman S; Gaseitsiwe S
    J Antimicrob Chemother; 2023 Oct; 78(10):2489-2495. PubMed ID: 37585352
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Indirect comparison of 48-week efficacy and safety of long-acting cabotegravir and rilpivirine maintenance every 8 weeks with daily oral standard of care antiretroviral therapy in participants with virologically suppressed HIV-1-infection.
    Chounta V; Snedecor SJ; Wu S; Van de Velde N
    BMC Infect Dis; 2022 May; 22(1):428. PubMed ID: 35508986
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The future of long-acting cabotegravir plus rilpivirine therapy: deeds and misconceptions.
    Rusconi S; Santoro MM; Capetti AF; Gianotti N; Zazzi M
    Int J Antimicrob Agents; 2022 Sep; 60(3):106627. PubMed ID: 35760225
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transient Viremia in Young Adults With HIV After the Switch to Long-Acting Cabotegravir and Rilpivirine: Considerations for Dosing Schedule and Monitoring.
    Rakhmanina N; Richards K; Adeline Koay WL
    J Acquir Immune Defic Syndr; 2023 Mar; 92(3):e14-e17. PubMed ID: 36480701
    [No Abstract]   [Full Text] [Related]  

  • 40. Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study.
    Orkin C; Oka S; Philibert P; Brinson C; Bassa A; Gusev D; Degen O; García JG; Morell EB; Tan DHS; D'Amico R; Dorey D; Griffith S; Thiagarajah S; St Clair M; Van Solingen-Ristea R; Crauwels H; Ford SL; Patel P; Chounta V; Vanveggel S; Cutrell A; Van Eygen V; Vandermeulen K; Margolis DA; Smith KY; Spreen WR
    Lancet HIV; 2021 Apr; 8(4):e185-e196. PubMed ID: 33794181
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.